News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Moberg Pharma AB (Formerly known as Moberg Derma) Reports Positive Interim Results In Phase II Clinical Study Of MOB-015



12/13/2013 9:11:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--Regulatory News:

Moberg Pharma AB (OMX:MOB)(STO:MOB) today announced positive interim results from its ongoing phase ll study of MOB-015. After six months of treatment with MOB-015, 40 per cent of the patients were mycologically cured and no safety concerns were identified. MOB-015 is a novel topical formulation of terbinafine for the treatment of nail fungus (onychomycosis).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES